Tag: Cancer: Kidney
Adjuvant Pembrolizumab Beneficial in Renal Cell Carcinoma
Rate of disease-free survival at 24 months higher with pembrolizumab versus placebo following nephrectomy
Occult Brain Mets Detected in Patients With Advanced Renal Cancer
Asymptomatic brain metastases incidentally diagnosed in about 4 percent of patients with mRCC during clinical trial screening
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC
Immunotherapy Combo Treats Advanced Kidney Cancer
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib
Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
10-year disease-specific survival 94 percent; 10-year risk for hemodialysis only 2.3 percent
Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors
Chemo Ups Disease-Free Survival in Upper Tract Urothelial Cancer
Gemcitabine-platinum combination therapy tied to improved survival after nephroureterectomy
Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression-free survival longer in those receiving tivozanib as third- or fourth-line therapy
